By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience announced after the close of the market on Thursday that it has reached an agreement with Premier healthcare alliance to offer members of the alliance Meridian's illumigene C. difficile and illumigene Group B Streptococcus molecular tests.

Meridian will offer the two tests to the 2,500 US hospitals and more than 81,000 other healthcare sites that are part of Premier at specially negotiated prices.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.